Clinical Trial

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-986521 following single and multiple ascending doses of BMS-986521 in healthy adult participants, and to evaluate potential food effects on BMS-986521 exposure.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-02.
Status change: Not Yet Recruiting → Recruiting 2026-01-05
Trial Details
NCT Number NCT07283263
Lead Sponsor Bristol-Myers Squibb
Conditions Healthy Volunteers
Enrollment 106 participants
Start Date 2025-12-23
Primary Completion 2026-11-17 (estimated)
Study Completion 2026-11-17 (estimated)
Updated on ClinicalTrials.gov 2026-01-07